Understanding and managing quality of the potential risks of existing and new pharmaceutical products have never been important than it is today.

Ensuring this performance is made with an efficient and profitable way, supported with good expertise, processes and systems, that are essential to the survival of medicine over the market.

The legislation has made that pharmacovigilance is still primordial and the stakeholders have focus more over the aspect of the management and supervision of risks.